ProQR Therapeutics
PRQR
30 hedge funds and large institutions have $130M invested in ProQR Therapeutics in 2014 Q3 according to their latest regulatory filings, with 30 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$15.2M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$12.3M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$11.2M |
| 4 |
Jennison Associates
New York
|
+$10.1M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$8.8M |
Top Sellers
PRQR Hedge Fund Activity: Q3 2014 in Review
30 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q3 2014, worth a combined $130M.
Buyers outnumbered sellers: 30 funds opened new PRQR positions and 0 closed out — a net gain of 30 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $15.2M.
- 30 institutional investors held ProQR Therapeutics (PRQR) as of Q3 2014, up from 0 in Q2 2014.
- Funds reported $130M of ProQR Therapeutics stock for Q3 2014.
- 30 funds opened new ProQR Therapeutics positions in Q3 2014 and 0 closed out, a net change of +30 holders.
- The largest ProQR Therapeutics buyer in Q3 2014 was OrbiMed, an estimated $15.2M added.
Based on aggregated 13F filings for Q3 2014.